Sona Nanotech Begins Clinical Trial for Late-Stage Cancer Patients Using THT Therapy

Sona Nanotech has begun a clinical trial for its THT therapy to treat late-stage melanoma patients. The therapy, classified as a device, aims to make tumors more visible to the immune system, potentially leading to tumor shrinkage and longer survival. The first patient has been dosed in Santiago, Chile, and the trial will follow patients for 28 days to assess safety, tolerability, and efficacy.

Halifax, Nova Scotia — Sona Nanotech Inc. (SONA, OTCQB: SNANF), an oncology-focused life sciences company, has announced the commencement of an early feasibility study for its Targeted Hyperthermia Therapy (THT) to treat late-stage melanoma patients. The study, conducted in Santiago, Chile, aims to assess the safety, tolerability, and preliminary efficacy of THT. The first patient has been dosed, marking a significant milestone in the company's development of innovative cancer therapies.

The THT therapy, classified as a medical device, leverages gold nanorods to deliver therapeutic heat to tumors via infrared light. This heat stimulates the immune system, potentially leading to tumor shrinkage and increased survival rates for patients with advanced melanoma. The study will follow patients for 28 days to evaluate the treatment's impact on tumor growth inhibition, immune system engagement, and overall tolerability.

According to Dr. Carman Giacomantonio, Sona's Chief Medical Officer, "Our unique therapy aims to modify tumors, making them more visible to the immune system. This study will provide key insights into the safety and feasibility of our THT in a clinical setting. Success in this study will enable us to proceed to more comprehensive trials."

David Regan, CEO of Sona Nanotech, commented, "Reaching this first dosing is a significant milestone achieved through years of research and preclinical studies. We plan to quickly follow this critical first clinical step with a second, more expansive human trial, as well as a peer-reviewed article detailing our findings."

The study, designed to assess THT's safety, tolerability, and preliminary efficacy, includes two treatments of THT, one week apart, for patients with advanced melanoma who are, or have been on, standard of care immunotherapy protocols but have failed to respond or progressed during treatment. The study is expected to generate an initial readout of results this summer, with final results expected in the fall.

Sona Nanotech believes that THT may offer benefits over current standard of care immunotherapy treatments, which have shown limited response rates and can have undesirable side effects. The company's gold nanorod particles are cetyltrimethylammonium (CTAB) free, eliminating toxicity risks associated with other gold nanorod technologies.

This development underscores Sona Nanotech's commitment to advancing innovative cancer therapies. The company's proprietary technology promises to be safe, effective, minimally invasive, and cost-competitive, making it a valuable adjunct to existing cancer treatments.

References:
[1] https://www.tradingview.com/news/reuters.com,2025-07-07:newsml_NFC6z0SRF:0-first-patient-dosed-in-early-feasibility-study-trial-of-its-cancer-therapy/
[2] https://www.marketscreener.com/quote/stock/PDS-BIOTECHNOLOGY-CORPORA-56049174/news/PDS-Biotechnology-Corporation-Announces-Colorectal-Cancer-Cohort-of-Phase-2-Clinical-Trial-with-PDS0-50480476/